NFKB1 and Hypercholesterolemia: In hypercholesterolemia rats, cilostazol reportedly exerted anti-inflammatory effects by inhibiting the PLC/PKC-α/p38/IκB-α/NF-κB signaling pathway (Brazão et al., 2023), thereby alleviating hypercholesterolemia-induced inflammatory cardiac damage (de Oliveira Lopes et al., 2022).